What is the administration route of Olaparib (olaparib) for a patient with progressive ovarian cancer (Ca ovariorum) stage IIB, pT2bN0M0G3, post-operative and post-chemotherapy?

From the Guidelines

Olaparib should be taken orally in tablet form, typically 300 mg (two 150 mg tablets) twice daily, for a total daily dose of 600 mg, as recommended by the most recent guidelines 1. You'll need to take these tablets approximately 12 hours apart, with or without food. Olaparib is used as a maintenance therapy for advanced ovarian cancer, particularly in cases with BRCA mutations or homologous recombination deficiency. Since your cancer has progressed after surgery and multiple rounds of chemotherapy, olaparib may help prevent further progression. Common side effects include fatigue, nausea, anemia, vomiting, and diarrhea. Your doctor will monitor your blood counts regularly, as olaparib can cause bone marrow suppression. It's essential to take the medication exactly as prescribed without missing doses. If you experience severe side effects, your doctor may temporarily interrupt treatment or reduce the dose rather than stopping completely. Be sure to inform your healthcare team about all medications you're taking, as certain drugs can interact with olaparib. The recommended dose of olaparib is supported by high-quality evidence from recent studies, including the SOLO-1 trial 1 and the ASCO guideline 1. These studies demonstrate the efficacy and safety of olaparib in maintaining progression-free survival in patients with advanced ovarian cancer. Additionally, the NCCN guidelines 1 provide recommendations for the use of olaparib in maintenance therapy for ovarian cancer, further supporting its use in this context. Overall, the evidence suggests that olaparib is a valuable treatment option for patients with advanced ovarian cancer, and its use should be considered in accordance with current guidelines and recommendations.

From the FDA Drug Label

Olaparib The FDA drug label does not answer the question.

From the Research

Olaparib Administration

• Olaparib is administered as 300 mg tablets, taken twice daily until disease progression or unacceptable toxicity 2
• The drug is orally active and has been shown to be effective in both maintenance and treatment settings for ovarian cancer 3
• Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor, which works by targeting DNA repair mechanisms 4

Dosage and Treatment Duration

• The recommended dosage of olaparib is 300 mg twice daily, with no specific treatment duration mentioned in the studies 2
• Patients with platinum-sensitive relapsed ovarian cancer, who have received at least two prior lines of platinum-based chemotherapy, can receive olaparib until disease progression or unacceptable toxicity 2

Safety Profile

• The safety profile of olaparib is consistent with its known safety profile, with common class toxicities including hematologic effects, gastrointestinal effects, and fatigue 3
• Grade ≥ 3 treatment-emergent adverse events were reported in 29.4% of patients, with anemia being the most common (13.6%) 2